External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Krishna Institute of Medical Sciences / Equity Bottom-Up

<ul><li>Industry occupancies in Telangana and AP have been declining due to bed oversupply, which has increased fourfold in the past three years.</li><li>This trend has been evident among key players such as KIMS, Apollo, and Aster DM over the last six quarters.</li><li>Q1FY25 occupancies highlighted softness in KIMS' matured hospitals, which constitute 50% of its revenue from Telangana and AP. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Industry occupancies in Telangana and AP have been declining due to bed oversupply, which has increased fourfold in the past three years.This trend has been evident among key players such as KIMS, Apollo, and Aster DM over the last six quarters.Q1FY25 occupancies highlighted softness in KIMS' matured hospitals, which constitute 50% of its revenue from Telangana and AP. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences Ltd - Lower Occupancies; Higher ARPOB

External broker reports(aggregated public sources), Prabhudas Lilladhar

Prabhudas Lilladhar

Prabhudas Lilladher is one of India's leading research based financial services organisation.

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences We hosted Dr.</li><li>Abhinay Bollineni, CEO of Krishna Institute of Medical Sciences (KIMS), for 2 days NDR at Mumbai.</li><li>The management indicated that KIMS will continue to grow at double digits with Sunshine and Nagpur units driving growth in the near term.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences We hosted Dr.Abhinay Bollineni, CEO of Krishna Institute of Medical Sciences (KIMS), for 2 days NDR at Mumbai.The management indicated that KIMS will continue to grow at double digits with Sunshine and Nagpur units driving growth in the near term.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute of Medical Sciences - Growth to Improve

<ul><li>Financial Performance: In Q3FY24, the company achieved consolidated revenue of Rs 606 Cr, up 7.8%/-7.1% YoY/QoQ.</li><li>It missed our estimates, which were primarily driven by low occupancies and ARPOBs in Telangana and AP assets on account of factors such as election in Telangana, decline in elective and transplant work, one-time expenses for innovation work and cyclone in Vizaz.</li><li>The consolidated occupancies exhibited an improvement of 480bps/(-420bps) YoY/QoQ reaching 72.2%.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Financial Performance: In Q3FY24, the company achieved consolidated revenue of Rs 606 Cr, up 7.8%/-7.1% YoY/QoQ.It missed our estimates, which were primarily driven by low occupancies and ARPOBs in Telangana and AP assets on account of factors such as election in Telangana, decline in elective and transplant work, one-time expenses for innovation work and cyclone in Vizaz.The consolidated occupancies exhibited an improvement of 480bps/(-420bps) YoY/QoQ reaching 72.2%.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute Of Medical Sciences Ltd - STRONG OPERATING CASH FLOWS & ROCE

<ul><li>In Q2FY24, the company achieved consolidated revenue of Rs 652 Cr, up 15.7%.</li><li>It surpassed our estimates and was primarily driven by enhancements in occupancies and ARPOBs.</li><li>The consolidated occupancies exhibited an impressive YoY improvement of 380bps, reaching 76.4%. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

In Q2FY24, the company achieved consolidated revenue of Rs 652 Cr, up 15.7%.It surpassed our estimates and was primarily driven by enhancements in occupancies and ARPOBs.The consolidated occupancies exhibited an impressive YoY improvement of 380bps, reaching 76.4%. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Krishna Institute Of Medical Sciences Ltd - Growth Led by Higher Occupancies and ARPOB

Thematic (Sector/Industry)

<ul><li>Q1FY25 Pharma Coverage Performance: In Q1FY25, the Pharma Coverage universe posted robust revenue growth of 11%/4% YoY/QoQ, driven by a strong domestic market, new launches (especially Darunavir, DDR D, gMyrbetriq, and gSpiriva), lower price erosion, gross margin expansion through cost optimization, and growth in the US base business portfolio.</li><li>EBITDA margin improved by a healthy ~250bps/120bps YoY/QoQ amidst normalizing cost inflation and stabilizing prices.</li><li>US Base Business Momentum: The US base business maintained healthy momentum, with new product launches offsetting single-digit price erosion.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Q1FY25 Pharma Coverage Performance: In Q1FY25, the Pharma Coverage universe posted robust revenue growth of 11%/4% YoY/QoQ, driven by a strong domestic market, new launches (especially Darunavir, DDR D, gMyrbetriq, and gSpiriva), lower price erosion, gross margin expansion through cost optimization, and growth in the US base business portfolio.EBITDA margin improved by a healthy ~250bps/120bps YoY/QoQ amidst normalizing cost inflation and stabilizing prices.US Base Business Momentum: The US base business maintained healthy momentum, with new product launches offsetting single-digit price erosion.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India

Krishna Institute of Medical Sciences Limited provides hospital services. The Hospital offers medical and surgical, renal and cardiac sciences, oncology, orthopaedics, organ transplantation, neurosciences, and other health care services. Krishna Institute of Medical Sciences serves patients in India.

Krishna Institute of Medical Sciences (KIMS IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Krishna Institute of Medical Sciences (KIMS IN)

Krishna Institute of Medical Sciences Ltd - Lower Occupancies; Higher ARPOB

Industry occupancies in Telangana and AP have been declining due to bed oversupply, which has increased fourfold in the past three years.

Axis Direct

Krishna Institute of Medical Sciences - Growth to Improve

Prabhudas Lilladher's research report onKrishna Institute of Medical Sciences. We hosted Dr.Abhinay Bollineni, CEO of Krishna Institute of Medical...

Prabhudas Lilladhar

Krishna Institute Of Medical Sciences Ltd - STRONG OPERATING CASH FLOWS & ROCE

Additionally, there was a 3.2%/-1.3% YoY/QoQ rise in ARPOB to Rs 30,741 during Q3FY24 which was below the industry levels.

Axis Direct

Krishna Institute Of Medical Sciences Ltd - Growth Led by Higher Occupancies and ARPOB

In Q2FY24, the company achieved consolidated revenue of Rs 652 Cr, up 15.7%. It surpassed our estimates and was primarily driven by enhancements in...

Axis Direct

Top Sector Ideas Pharma - (Q1FY25)

n Q1FY25, the Pharma Coverage universe posted robust revenue growth of 11%/4% YoY/QoQ, driven by a strong domestic market

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)